Robert Barrow

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylamide) in adult patients with attention deficit hyperactivity disorder. The company said it expects...

Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Tuesday that Robert Barrow has been appointed CEO and member of the board of directors. Barrow, an accomplished pharmaceutical executive and a recognized leader in the psychedelic industry, is...

This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn. In learning more about the changes that have taken place since, Benzinga spoke with Robert Barrow, the firm’s chief development...

Mind Medicine Appoints Maria A. Oquendo To Scientific Advisory Board Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced recently that it has tapped Maria A. Oquendo, M.D., Ph.D. to its scientific advisory board. Oquendo is a Ruth Meltzer...

Leafly Holdings Taps Suresh Krishnaswamy As New CFO The cannabis information platform Leafly Holdings, Inc. recently disclosed that it has appointed Suresh Krishnaswamy as its new CFO, ahead of going public via a business combination with a special purpose acquisition company Merida Merger Corp. (...

A psychedelics-focused medicine company MindMed (NASDAQ: MNMD) reported Monday that has been added to the FTSE Russell 3000 index, effective June 25th. The FTSE Russell 3000 index measures the performance of the 3,000 largest companies in the United States. As part of its...

Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co-founder and CEO, would step down. Benzinga spoke with Rahn on what the transition means for MindMed, the industry ...

Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland. This “clinic model” will study and...